OOIR: Observatory of International Research

Papers

(The TQCC of Biodrugs is 12. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-01-01 to 2026-01-01.)

Article	Citations
Clinical Features and Drug Retention of TNF Inhibitors in Older Patients with Ankylosing Spondylitis: Results from the KOBIO Registry	301
Targeting Neurological Aspects of Mucopolysaccharidosis Type II: Enzyme Replacement Therapy and Beyond	228
Emerging Therapy in Osteoarthritis: Mesenchymal Stem Cells, Secretomes, and Using Hydrogels to Enhance Efficacy	106
The Path to Accessible Care: Development and Impact of Eculizumab Biosimilars for Paroxysmal Nocturnal Hemoglobinuria and Atypical Hemolytic Uremic Syndrome	105
Recurring Fatigue After Biologic Administration: Patient-Reported Data from the Dutch Biologic Monitor	86
Comparative Safety Profiles of Oncology Biosimilars: A Systematic Review and Network Meta-analysis	81
Targeting Amyloid Fibrils by Passive Immunotherapy in Systemic Amyloidosis	77
New and Emerging Biological Therapies for Myasthenia Gravis: A Focussed Review for Clinical Decision-Making	72
Modification of Extracellular Vesicle Surfaces: An Approach for Targeted Drug Delivery	61
In Vitro Biological Characterization of Recombinant Insulin Aspart from Biogenomics and Originator Insulin Aspart	52
Acknowledgement to Referees	49
Localised Delivery of Macromolecules to the Large Intestine: Translation to Clinical Trials	45
Historical Overview of Regulatory Approvals and PMDA Assessments for Biosimilar Products in Japan During 2009–2022	45
CAR-T Cells and the Kidney: Insights from the WHO Safety Database	41
A Tale of Two New Targets for Hypertriglyceridaemia: Which Choice of Therapy?	36
Switching from One Biosimilar to Another Biosimilar of the Same Reference Biologic: A Systematic Review of Studies	33
The Present and Future of Monoclonal Antibody Therapies for Multiple Sclerosis	33
Antisense Oligonucleotide Therapy: From Design to the Huntington Disease Clinic	33
Correction to: Immunotherapy in Gastro-Oesophageal Cancer: Current Practice and the Future of Personalised Therapy	33
Cell Engineering for Increasing Production of Recombinant Proteins in Mammalian Cells	32
Progress and Challenges in the Treatment of Fabry Disease	30
First-Line Treatment of Advanced Non-Small-Cell Lung Cancer with Immune-Checkpoint Inhibitors: New Combinations and Long-Term Data	30
Malaria Vaccines: Progress to Date	30
Correction: Dystrophin- and Utrophin-Based Therapeutic Approaches for Treatment of Duchenne Muscular Dystrophy: A Comparative Review	30
Characterization of Biosimilar Monoclonal Antibodies and Their Reference Products Approved in Japan to Reveal the Quality Characteristics in Post-approval Phase	30

Demand- Versus Supply-Side Policies in Market Penetration of Biosimilars: Which is More Effective?	30
Do the Outcomes of Clinical Efficacy Trials Matter in Regulatory Decision-Making for Biosimilars?	28
Multispecific Antibodies Targeting PD-1/PD-L1 in Cancer	27
Biochemical Amenability in Fabry Patients Under Chaperone Therapy—How and When to Test?	26
Pharmacokinetics, Safety, and Immunogenicity of a Biosimilar of Nivolumab (LY01015): A Randomized, Double-Blind, Parallel-Controlled Phase I Clinical Trial in Healthy Chinese Male Subjects	26
Real-World Evidence on the Effectiveness and Safety of Spesolimab in the Treatment of Generalized Pustular Psoriasis Flares: A Case Series	24
Enhancing the Response Rate to Recombinant Uricases in Patients with Gout	23
Extracellular Vesicles Derived from Mesenchymal Stem Cells: A Potential Biodrug for Acute Respiratory Distress Syndrome Treatment	23
Defining a Framework for Sustainable Global Biosimilars Markets Using Findings from a Targeted Literature Review	22
Regulatory Evaluation of Biosimilars: Refinement of Principles Based on the Scientific Evidence and Clinical Experience	21
Analytical Data and Single-Dose PK are Sufficient to Conclude Comparable Immunogenicity for Biosimilars: An Ustekinumab Case Study	21
Interleukin-23 versus Interleukin-17 Inhibitors in Preventing Incidental Psoriatic Arthritis in Patients with Psoriasis: A Real-World Comparison From the TriNetX US Collaborative Network	21
Exploring the Use of Monoclonal Antibodies and Antiviral Therapies for Early Treatment of COVID-19 Outpatients in a Real-World Setting: A Nationwide Study from England and Italy	21
Non-small Cell Lung Cancer with EGFR or HER2 Exon 20 Insertion Mutations: Diagnosis and Treatment Options	21
Novel Migraine Therapies May Reduce Public and Personal Disadvantages for People with Migraine	20
Long-Term Safety and Effectiveness of PF-05280014 (a Trastuzumab Biosimilar) Treatment in Patients with HER2-Positive Metastatic Breast Cancer: Updated Results of a Randomized, Double-Blind Study	20
Targeted Gene Insertion: The Cutting Edge of CRISPR Drug Development with Hemophilia as a Highlight	20
Interleukin-1 Antagonists for the Treatment of Recurrent Pericarditis	19
Interleukin-17 Inhibitors in the Treatment of Hidradenitis Suppurativa	19
Understanding IgM Structure and Biology to Engineer New Antibody Therapeutics	18
Islet Cell Replacement and Regeneration for Type 1 Diabetes: Current Developments and Future Prospects	18
TL1A Inhibition in Inflammatory Bowel Disease: A Pipeline Review	17
Tolerability and Reactogenicity Profile of mRNA SARS-Cov-2 Vaccines from a Mass Vaccination Campaign in a Tertiary Hospital: Between-Vaccine and Between-Population Prospective Observational Study (Vig	17
Efficacy and Safety of Candidate Biosimilar CT-P43 Versus Originator Ustekinumab in Moderate to Severe Plaque Psoriasis: 28-Week Results of a Randomised, Active-Controlled, Double-Blind, Phase III Stu	17
Use of Semaglutide (Wegovy) in Adults in France: A Nationwide Drug Utilization Study	16
Impact of Introducing Infliximab Biosimilars on Total Infliximab Consumption and Originator Infliximab Prices in Eight Regions: An Interrupted Time-Series Analysis	16
Safety of Biological Therapies for Severe Asthma: An Analysis of Suspected Adverse Reactions Reported in the WHO Pharmacovigilance Database	16
The Use of Biologics for Thyroid Eye Disease	15
HLX11, a Proposed Pertuzumab Biosimilar: Pharmacokinetics, Immunogenicity, and Safety Profiles Compared to Three Reference Biologic Products (US-, EU-, and CN-Approved Pertuzumab) Administered to Heal	15
Extracellular Vesicles and Immune Activation in Solid Organ Transplantation: The Impact of Immunosuppression	15
Next-Generation Anti-TNFα Agents: The Example of Ozoralizumab	14
Bioanalytical Methods and Strategic Perspectives Addressing the Rising Complexity of Novel Bioconjugates and Delivery Routes for Biotherapeutics	14
Recurrent Clostridioides difficile Infection: Current Clinical Management and Microbiome-Based Therapies	14
Acute Kidney Injury from Intravitreal Anti-vascular Endothelial Growth Factor Drugs: A Systematic Review and Meta-analysis of Randomized Controlled Trials	14
Going Beyond Host Defence Peptides: Horizons of Chemically Engineered Peptides for Multidrug-Resistant Bacteria	13
Biosimilar Uptake in Spain from 2016 to 2023: Analysis Based on Official Data Collection	13
Targeting the Inside of Cells with Biologicals: Toxin Routes in a Therapeutic Context	12
Monoclonal Antibody Generation Using Single B Cell Screening for Treating Infectious Diseases	12
Advances of Antimicrobial Peptides in the Treatment of Multidrug-Resistant Bacteria	12
Assessing Immunogenicity of Biologic Drugs in Inflammatory Joint Diseases: Progress Towards Personalized Medicine	12
Impact of Early Access Reform on Oncology Innovation in France: Approvals, Patients, and Costs	12
CRISPR-Cas System: A New Dawn to Combat Antibiotic Resistance	12